Lateral Flow Assays Market Size

Request Free Sample Copy

Report ID: 4871
Published Date: Sep 10, 2025
Report Format: PDF, PPT

Buy Now

Lateral Flow Assays Market Outlook:

Lateral Flow Assays Market size was over USD 9.76 billion in 2025 and is anticipated to cross USD 17.81 billion by 2035, witnessing more than 6.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of lateral flow assays is assessed at USD 10.3 billion.

The growth of the market is mainly due to the increasing prevalence of infectious diseases. According to the World Health Organization (WHO), infectious diseases are the leading cause of death worldwide, accounting for about 25% of all deaths worldwide.

Increasing demand for diagnostic test products that use lateral flow technology for the detection of diseases, is further predicted to drive the lateral flow assays market. In 2020, an estimated 38 million people were living with HIV/AIDS worldwide, with 1.5 million new infections and 690,000 deaths. Tuberculosis (TB) remains one of the top 13th causes of death globally with about 10.6 million new cases and 1.6 million deaths in 2021.

Browse key industry insights with market data tables & charts from the report:

Lateral Flow Assays Market Size, Share & Growth Report 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of lateral flow assays is assessed at USD 10.3 billion.

The global lateral flow assays market size surpassed USD 9.76 billion in 2025 and is projected to witness a CAGR of around 6.2%, crossing USD 17.81 billion revenue by 2035.

Asia Pacific lateral flow assays market will secure around 34% share by 2035, driven by high burden of infectious diseases requiring rapid diagnosis.

Key players in the market include Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F.Hoffmann-La Roche AG, QIAGEN N.V., Siemens Healthineers AG, Thermo Fisher Scientific, Inc., Merck kGaA, PerkinElmer Inc.